Why Where You Are Born Still Determines Whether You Live or Die

The relationship between geography and survival is not accidental. It is the cumulative result of decades of underinvestment, structural inequality, and a global health architecture that continues to prioritise the concerns of wealthy nations over the needs of those who bear the highest disease burden.

A child born in Sierra Leone has a 1-in-20 chance of dying before their fifth birthday. A child born in Finland has a 1-in-500 chance. This is not a story about medicine, or science, or the limits of what is biologically possible. The medicine exists. The interventions are known. The science has not changed. What has changed — what determines survival — is the system surrounding the child at the moment of birth.

The Architecture of Inequality

Global health has a data problem — not a shortage of data, but a surplus of it that we routinely fail to act on. We know that maternal mortality rates in sub-Saharan Africa are 130 times higher than in high-income countries. We know that 80% of premature deaths from noncommunicable diseases occur in low- and middle-income countries. We know that a person's likelihood of receiving treatment for hypertension or diabetes is almost entirely determined by their country of birth and its position in the global economic order.

The uncomfortable truth is that the global health system was not designed to address these inequities. It was designed — often with genuine good intentions — by actors whose primary accountability lies elsewhere: to donor governments, to shareholders, to institutional mandates that do not begin and end with the health of the people who need it most.

What Health Economics Reveals

When you apply a health economics lens to these questions, the picture becomes both clearer and more troubling. The cost-effectiveness thresholds used to determine which interventions receive funding in high-income countries are simply inapplicable in settings where health systems are funded at $50 per person per year. A QALY-based framework developed in the context of NHS England does not translate cleanly to a district hospital in northern Nigeria operating without reliable electricity.

This is not a criticism of health economics as a discipline. It is a call for the discipline to expand its field of vision — to develop frameworks that are genuinely applicable across income settings, and that capture the equity dimensions that current tools systematically underweight.

Three Continents, Three Systems

My own experience across Nigeria, China, and Scotland has given me a particular view of how different the same problem looks from different positions in the global health system. In Nigeria, I watched patients travel for hours to reach a pharmacist, only to find that the medication they needed was unavailable because the supply chain had broken down somewhere between the manufacturer and the health facility.

In China, I saw what a different kind of public investment in health infrastructure can produce — a system with genuine capacity for rapid response, built through sustained political will and economic prioritisation of health as a developmental investment. Whatever the limitations of that system, its ambition was instructive.

In Scotland, I encountered a universal health system under pressure — not from lack of resources by global standards, but from a particular combination of rising demand, workforce challenges, and the accumulated effects of chronic underinvestment in prevention. What the NHS faces is a different problem from what Nigerian health systems face, but the structural logic is related: health systems everywhere are being asked to do more with less, and the consequences fall hardest on those with least.

What Actually Changes Outcomes

The evidence on what actually produces better health outcomes at population level is remarkably consistent. It is not primarily about clinical innovation, though that matters. It is about the fundamentals: reliable primary care, functioning pharmaceutical supply chains, a trained and distributed health workforce, financing mechanisms that protect the poor from catastrophic health expenditure, and political systems that are genuinely accountable to the populations they serve.

Universal Health Coverage is not just a worthy aspiration. It is an achievable technical specification, if we are honest about what achieving it actually requires. Countries that have made the transition to UHC have not done so by accident. They have done so through sustained political commitment, smart financing reform, and the willingness to prioritise health as a component of economic development rather than simply a cost of it.

The Policy Levers We Have Yet to Pull

There are things we know how to do that we are not doing. We know that community health worker programmes, when properly supported and remunerated, extend the reach of health systems into communities that formal infrastructure cannot reach. We know that social prescribing — connecting patients to non-clinical support that addresses the social determinants of their health — reduces downstream demand on expensive clinical services. We know that pharmaceutical supply chain reform, including investment in local manufacturing capacity, reduces dependence on global supply chains that consistently fail low-income countries in moments of crisis.

We know all of this. The question is not what to do. The question is whether the political will exists to do it — and whether those of us working in global health are willing to be honest about the structural changes, in financing, in governance, in the global trade rules that govern pharmaceutical access, that genuine health equity actually requires.

Where you are born should not determine whether you live or die. That it currently does is not a fact of nature. It is a consequence of choices — and choices can be changed.